Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 13

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 13
---
 to the closing of this offering, we intend to complete a forward                                                                         
 split of our outstanding Ordinary Shares, at a ratio of 2.5-for-1. All share numbers in this prospectus have been adjusted to give prospective 
 effect to the Split, except in the historical financial statements or as otherwise indicated. We have convened a general meeting of our        
 shareholders to be held on March 20, 2025, to approve the Split.                                                                               |
| Use                                          
 of proceeds                                  |     | We expect to receive approximately $8                                                                                                          
 million in net proceeds from the sale of  Ordinary Shares in this offering in this offering (approximately $9.4 million if                     
 the Representative exercises its over-allotment option in full), based upon an assumed public offering price of $11.00 per                     
 Ordinary Share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the               
 underwriting discounts and commissions and estimated offering expenses payable by us.                                                          
 We currently expect to use the net proceeds                                                                                                    
 from this offering for the following purposes:                                                                                                 |

| ● | approximately $4.5 million for development activities (including                        
 the completion of our pivotal trial) and preparation of the PMA submission for GelrinC; |

| ● | approximately $1.0 million for operations (manufacturing, regulatory 
 affairs and patents);                                                |

| ● | approximately $0.5 million for research and development activities; |

| ● | approximately $0.5 million for EU marketing development (Medical 
 Device Regulation qualification and scaleup);                    |

| ● | approximately $0.8 million for the repayment of the Bridge Loan,                                                                   
 the 2024 Loan Agreements and the December 2024 Loan (each, as defined below) and accrued interest and applicable risk premium; and |

| ● | the remainder                                                                        
 for working capital and general corporate purposes and possible future acquisitions. |

| The amounts                                                                                                                        
 and schedule of our actual expenditures will depend on multiple factors. As a result, our management will have broad discretion in 
 the application of the net proceeds of this offering. For additional information regarding the repayment of the Bridge Loan, see   
 “Certain Relationships and Related Party Transactions – Other Financings.”                                                         |

<div align='center'>11</div>

| Risk                          
 factors                       |     | Investing in                                                                                                                           
 our securities involves a high degree of risk. You should read the “Risk Factors” starting on page 14 of this